rEVO Biologics, a biotech developing a recombinant protein for the treatment of preeclampsia, postponed its IPO on Friday. The Framingham, MA-based company was founded in 1993 and booked $18 million in sales for the 12 months ended June 30, 2014. Piper Jaffray and Guggenheim Securities were set to be the joint bookrunners on the deal.
